PDCD1 and neoplasm: New findings have revealed interactions between combining PD-1/PD-L1 inhibitors with other immune checkpoint inhibitors, angiogenesis inhibitors or chemotherapies, encouraging the immune response and hindering the escape of tumor cells (Antonia et al., 2018).